← FDA DRUG APPROVALS

FDA BLA · BLA761399

OMLYCLO

Sponsor: CELLTRION INC

APPLICATION
BLA761399
TYPE
BLA
ORIGINAL APPROVAL
2025-03-07
LATEST ACTION
2025-12-01
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

OMLYCLOPrescription
OMALIZUMAB-IGEC 300MG/2ML · INJECTABLE · INJECTION
OMLYCLOPrescription
OMALIZUMAB-IGEC 75MG/0.5ML · INJECTABLE · INJECTION
OMLYCLOPrescription
OMALIZUMAB-IGEC 150MG/ML · INJECTABLE · INJECTION

Approval history

2025-12-01Manufacturing (CMC) · Supplement 4 · standardLabelAP
2025-03-07UNKNOWN · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →